1. PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis

   News item 23 April 2022 Pages: 1 - 1

2. Reminder of measures to prevent methotrexate-related nephrotoxicity

   News item 23 April 2022 Pages: 2 - 2

3. Warning against consumption of Miracle Mineral Solution

   News item 23 April 2022 Pages: 3 - 3

4. ISMP against criminalisation of medication errors

   Unknown 23 April 2022 Pages: 4 - 4

5. ADRs and noncompliance cause hospital admissions in Ethiopia

   Clinical study 23 April 2022 Pages: 5 - 5

6. Cardiac risks higher after COVID-19 infection than mRNA vaccine

   Clinical study 23 April 2022 Pages: 6 - 6

7. Early recognition of ICI-related AEs requires expertise

   Clinical study 23 April 2022 Pages: 7 - 7

8. Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients

   Clinical study 23 April 2022 Pages: 8 - 8

9. Nephrotoxic potential of drugs used in adult ICU

   Clinical study 23 April 2022 Pages: 9 - 9

10. PARP inhibitor safety profiles differ

    Clinical study 23 April 2022 Pages: 10 - 10

11. PPI use increases risk of liver-related adverse outcomes in cirrhosis

    Clinical study 23 April 2022 Pages: 11 - 11

12. Biological drugs safe for severe psoriasis in children

    Clinical study 23 April 2022 Pages: 12 - 12

13. Other adverse reaction research

    News item 23 April 2022 Pages: 13 - 13

14. Abatacept

    Case report 23 April 2022 Pages: 14 - 14

15. Abemaciclib/palbociclib/ribociclib

    Case report 23 April 2022 Pages: 15 - 15

16. Acenocoumarol/rituximab

    Case report 23 April 2022 Pages: 16 - 16

17. Acetazolamide/tozinameran

    Case report 23 April 2022 Pages: 17 - 17

18. Aciclovir

    Case report 23 April 2022 Pages: 18 - 18

19. Acitretin/ciclosporin

    Case report 23 April 2022 Pages: 19 - 19

20. Ad26.COV2-S/elasomeran/tozinameran

    Case report 23 April 2022 Pages: 20 - 20

21. Adalimumab

    Case report 23 April 2022 Pages: 21 - 21

22. Afatinib

    Case report 23 April 2022 Pages: 22 - 22

23. Afatinib/prednisolone/steroids

    Case report 23 April 2022 Pages: 23 - 23

24. Albumin human/antibacterials

    Case report 23 April 2022 Pages: 24 - 24

25. Albumin-human/amphotericin-b-liposomal interaction

    Case report 23 April 2022 Pages: 25 - 25

26. Alectinib

    Case report 23 April 2022 Pages: 26 - 26

27. Alendronic acid

    Case report 23 April 2022 Pages: 27 - 27

28. Alendronic-acid/colecalciferol

    Case report 23 April 2022 Pages: 28 - 28

29. Amikacin/clarithromycin

    Case report 23 April 2022 Pages: 29 - 29

30. Amiodarone

    Case report 23 April 2022 Pages: 30 - 30

31. Amlodipine/everolimus interaction

    Case report 23 April 2022 Pages: 31 - 31

32. Amoxicillin/clavulanic acid/cefepime

    Case report 23 April 2022 Pages: 32 - 32

33. Amoxicillin/penicillins

    Case report 23 April 2022 Pages: 33 - 33

34. Amphotericin-B

    Case report 23 April 2022 Pages: 34 - 34

35. Amphotericin-b-liposomal/cotrimoxazole

    Case report 23 April 2022 Pages: 35 - 35

36. Amphotericin-b/fluconazole

    Case report 23 April 2022 Pages: 36 - 36

37. Antibacterials

    Case report 23 April 2022 Pages: 37 - 37

38. Antibacterials/convalescent-anti-SARS-CoV-2-plasma/hydroxychloroquine

    Case report 23 April 2022 Pages: 38 - 38

39. Antibacterials/dexamethasone

    Case report 23 April 2022 Pages: 39 - 39

40. Antibacterials/ethambutol

    Case report 23 April 2022 Pages: 40 - 40

41. Antibacterials/micafungin

    Case report 23 April 2022 Pages: 41 - 41

42. Anticoagulants/AZD-1222

    Case report 23 April 2022 Pages: 42 - 42

43. Antifungals/glucocorticoids

    Case report 23 April 2022 Pages: 43 - 43

44. Antifungals/immunosuppressants

    Case report 23 April 2022 Pages: 44 - 44

45. Antiglaucomas/anti-inflammatories

    Case report 23 April 2022 Pages: 45 - 45

46. Antineoplastics

    Case report 23 April 2022 Pages: 46 - 46

47. Antineoplastics

    Case report 23 April 2022 Pages: 47 - 47

48. Antineoplastics

    Case report 23 April 2022 Pages: 48 - 48

49. Antineoplastics

    Case report 23 April 2022 Pages: 49 - 49

50. Antineoplastics

    Case report 23 April 2022 Pages: 50 - 50